Talphera Past Earnings Performance
Past criteria checks 0/6
Talphera has been growing earnings at an average annual rate of 44%, while the Pharmaceuticals industry saw earnings growing at 10.4% annually. Revenues have been declining at an average rate of 28.5% per year.
Key information
44.0%
Earnings growth rate
52.3%
EPS growth rate
Pharmaceuticals Industry Growth | 7.3% |
Revenue growth rate | -28.5% |
Return on equity | -72.9% |
Net Margin | -1,580.2% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Talphera makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 1 | -10 | 12 | 5 |
30 Sep 23 | 0 | -11 | 14 | 0 |
30 Jun 23 | 0 | -14 | 16 | 0 |
31 Mar 23 | 2 | 42 | 26 | 0 |
31 Dec 22 | 0 | 54 | 17 | 3 |
30 Sep 22 | -2 | 69 | 2 | 0 |
30 Jun 22 | -1 | 65 | 7 | 0 |
31 Mar 22 | 2 | -31 | 27 | 0 |
31 Dec 21 | 0 | -17 | 15 | 0 |
30 Sep 21 | 4 | -36 | 33 | 0 |
30 Jun 21 | 3 | -37 | 30 | 0 |
31 Mar 21 | 6 | -33 | 31 | 0 |
31 Dec 20 | 5 | -40 | 36 | 0 |
30 Sep 20 | 5 | -46 | 41 | 0 |
30 Jun 20 | 4 | -50 | 46 | 0 |
31 Mar 20 | 2 | -55 | 48 | 0 |
31 Dec 19 | 2 | -53 | 45 | 0 |
30 Sep 19 | 2 | -51 | 40 | 0 |
30 Jun 19 | 2 | -51 | 34 | 0 |
31 Mar 19 | 2 | -49 | 27 | 0 |
31 Dec 18 | 2 | -47 | 21 | 0 |
30 Sep 18 | 2 | -44 | 17 | 0 |
30 Jun 18 | 3 | -45 | 16 | 0 |
31 Mar 18 | 5 | -48 | 16 | 0 |
31 Dec 17 | 8 | -52 | 17 | 0 |
30 Sep 17 | 14 | -51 | 17 | 0 |
30 Jun 17 | 16 | -50 | 17 | 0 |
31 Mar 17 | 17 | -48 | 16 | 0 |
31 Dec 16 | 17 | -43 | 16 | 0 |
30 Sep 16 | 13 | -44 | 16 | 0 |
30 Jun 16 | 25 | -28 | 14 | 0 |
31 Mar 16 | 22 | -25 | 13 | 0 |
31 Dec 15 | 19 | -24 | 14 | 0 |
30 Sep 15 | 18 | -28 | 15 | 0 |
30 Jun 15 | 7 | -32 | 17 | 0 |
31 Mar 15 | 5 | -34 | 19 | 0 |
31 Dec 14 | 5 | -33 | 18 | 0 |
30 Sep 14 | 33 | -2 | 17 | 0 |
30 Jun 14 | 28 | -13 | 15 | 0 |
31 Mar 14 | 29 | -20 | 12 | 0 |
31 Dec 13 | 30 | -23 | 10 | 0 |
30 Sep 13 | 4 | -52 | 8 | 0 |
30 Jun 13 | 3 | -49 | 8 | 0 |
Quality Earnings: R5XA is currently unprofitable.
Growing Profit Margin: R5XA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: R5XA is unprofitable, but has reduced losses over the past 5 years at a rate of 44% per year.
Accelerating Growth: Unable to compare R5XA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: R5XA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.7%).
Return on Equity
High ROE: R5XA has a negative Return on Equity (-72.93%), as it is currently unprofitable.